Dr. Anette Duensing

Home/Tag: Dr. Anette Duensing

LRG Webcast Series: GIST, TKI Treatment & Effects on Memory

This discussion reviewed CRCI in general, and how a person who is being treated for GIST could be affected. We also talked about strategies that can help ameliorate CRCI, new research on CRCI and GIST. we also gave advice on how cancer survivors can best cope with and care for themselves during this unusual global health event.

By |2020-07-20T11:34:41-04:00May 15th, 2020|GIST Education, Gleevec, Webcast|

Study Highlights Role of ABL1 in GIST Treated with Imatinib

A recent study published in Oncotarget, discussed the potential role of the kinase, ABL1 as a potential impediment to anti-tumor processes in GIST treated with imatinib mesylate. The Life Raft Group’s Research Team member, [...]

By |2018-10-30T09:23:31-04:00January 19th, 2017|News, Research|

LRG Research Team Member Anette Duensing Receives 2014 GIST Award

The GIST Group Switzerland recently awarded its Science Prize to Dr. Anette Duensing, Assistant Professor of Pathology at the University of Pittsburgh Cancer Institute, and a member of the LRG’s Research Team. GIST Group [...]

By |2018-09-10T10:19:51-04:00February 4th, 2015|News, Research|

Life Fest 2014: What’s New in the Science of GIST?

In addition to spending time catching up with fellow patients and caregivers and attending the myriad of useful workshops featured at Life Fest 2014, participants were treated to an update of what is new in [...]

By |2018-07-26T12:21:11-04:00December 8th, 2014|GIST Education, News, Research|

Strategies to rapidly identify and validate new therapies for GIST

By Dr. Anette Duensing, University of Pittsburgh Cancer Institute, and Dr. Maria Debiec-Rychter, KU Leuven, Belgium, LRG Research Team Dr. Maria Debiec-Rychter Dr. Anette Duensing Although most GISTs initially respond well [...]

By |2019-09-20T12:36:26-04:00October 24th, 2014|Drug Treatment, News, Research|

2013 LRG Research Team Progress Report

Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.

The Life Raft Group Attends 18th Annual CTOS Meeting in NYC

From October 30th to November 2nd the Life Raft Group staff members attended the annual Connective Tissue Oncology Society (CTOS) Meeting in NYC.

By |2019-09-20T11:36:08-04:00December 6th, 2013|Advocacy, Clinical Trials, Drug Treatment, News, Research|
Go to Top